# Kenvue

Type: Company (KVUE)

Source: GetYourBrief — https://getyourbrief.com/entity/kenvue
Canonical HTML page: https://getyourbrief.com/entity/kenvue

## Recent coverage (6 stories, network-wide)

### Over 500 Tylenol suits revived: Prenatal care guidelines under microscope
2026-07-25 19:57:02 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 2

The legal reinstatement of Tylenol-autism lawsuits pressures healthcare providers to reconcile conflicting evidence on acetaminophen safety in pregnancy, potentially altering clinical guidance, patient counseling, and EHR decision support.
Full story: https://gethealthbrief.com/story/tylenol-autism-lawsuits-revived-health

### 500+ Tylenol suits revived: $10B risk for Kenvue and OTC pharma
2026-07-25 19:56:51 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2

The 2nd Circuit ruling revives mass tort litigation linking prenatal acetaminophen to autism, exposing Kenvue and retailers to billions in potential liability. The decision hinges on admissibility of novel scientific evidence, challenging Daubert standards and regulatory orthodoxy.
Full story: https://getbiobrief.com/story/tylenol-autism-lawsuits-revived-bio

### J&J’s $100B Revenue Runway: How Next-Gen Drugs Are Plugging the Stelara Gap
2026-07-20 00:11:51 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

J&J’s Q2 2026 earnings beat underscores a successful pivot away from Stelara’s $10B peak. New oncology and immunology drugs are powering growth, with full-year revenue now expected to top $100B. For healthcare stakeholders, this signals pipeline resilience and a defensive stock offering amid sector headwinds.
Full story: https://gethealthbrief.com/story/jnj-100b-pharma-pipeline-stelara-gap-health

### BofA Lifts Johnson & Johnson Price Target on Robust Pipeline Momentum
2026-03-12 08:11:39 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bank of America has raised its price target for Johnson & Johnson (JNJ), citing a strengthened outlook for the company's pharmaceutical and MedTech pipelines. The upgrade reflects growing investor confidence in JNJ's post-Kenvue strategy, which prioritizes high-margin innovation in oncology, immunology, and surgical robotics.
Full story: https://gethealthbrief.com/story/bofa-raises-jnj-price-target-pipeline-growth

### Scientific Studies Rebut RFK Jr. Claims on Vaccines, Tylenol, and SSRIs
2026-02-25 12:41:54 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Recent large-scale clinical studies are directly contradicting public health claims made by Robert F. Kennedy Jr. regarding the safety profiles of vaccines, acetaminophen, and antidepressants. These findings provide a critical scientific defense for pharmaceutical manufacturers facing increased regulatory scrutiny and litigation risks.
Full story: https://getbiobrief.com/story/scientific-studies-rebut-rfk-claims-pharma

### Midweek Market Pulse: Moderna and SanDisk Lead Sector-Specific Volatility
2026-02-19 01:48:21 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 6

Investors are navigating a complex Wednesday session as major players in biotech, semiconductors, and leisure release pivotal updates. Market attention is centered on Moderna's pipeline diversification and SanDisk's recovery in the memory sector, signaling a shift toward fundamental-driven trading.
Full story: https://getfinancebrief.com/story/midweek-market-movers-moderna-sandisk-caesars

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.